Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer

Inclusion Criteria: * Male patients. Age \>18 years. * HLA-A\*0201 positive. * Histologically confirmed prostate cancer. * Minimum two (2) and maximum four (4) years after treatment with curative or salvage radiotherapy. * Serum testosterone within normal range. * Increasing PSA from a previous reference value on two (2) consecutive occasions at least one month apart and with a minimum of 2 ng/mL above nadir. * PSA doubling time is one (1) year or less. * No evidence of metastatic prostate cancer. * Karnofsky performance status ≥ 80. * Adequate organ function: * AST and ALT ≤ 2.0 x upper limit of normal (ULN); total serum bilirubin ≤ 1.5 x ULN * Calcium ≤ 2.6 mmol/L, serum creatinine ≤ 1.5 x ULN * Hb ≥ 100 g/L; absolute leukocyte count ≥ 3.0 x 109 /L; platelets ≥100 x 109 /L * Life expectancy ≥ 12 months. * Swedish or English speaking subjects only. * Written informed consent (subjects must be capable of providing their own informed consent). Exclusion Criteria: * Previous ablation of testis. * Radiologic evidence of metastatic disease. * Prior chemotherapy or investigational therapy/agents within 4 weeks. * Active bacterial, viral or fungal infection. * Carrier of HIV, HBV, or HCV. * Immunosuppressed (post splenectomy, post stem cell transplantation) or on immunosuppressive therapy other than inhaled or replacement corticosteroids. * Any other major illness or peripheral blood vein status that, in the investigator's judgement, will substantially increase the risk associated with sampling or participation in this study. * Subjects with cardiac demand pacemakers. * Any reason why, in the opinion of the investigator, the patient should not participate.